Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 189

Similar articles for PubMed (Select 22150035)

1.

Three months of rifapentine and isoniazid for latent tuberculosis infection.

Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team.

N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875.

2.

Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.

Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium.

JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158.

PMID:
25580725
3.

New regimens to prevent tuberculosis in adults with HIV infection.

Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE.

N Engl J Med. 2011 Jul 7;365(1):11-20. doi: 10.1056/NEJMoa1005136.

4.

Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.

Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE.

Am J Respir Crit Care Med. 2006 Apr 15;173(8):922-6. Epub 2006 Feb 10.

5.

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC; Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators.

Ann Intern Med. 2002 Oct 15;137(8):640-7.

PMID:
12379063
6.

Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.

Holland DP, Sanders GD, Hamilton CD, Stout JE.

Am J Respir Crit Care Med. 2009 Jun 1;179(11):1055-60. doi: 10.1164/rccm.200901-0153OC. Epub 2009 Mar 19.

7.

Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.

Jawahar MS, Rajaram K, Sivasubramanian S, Paramasivan CN, Chandrasekar K, Kamaludeen MN, Thirithuvathas AJ, Ananthalakshmi V, Prabhakar R.

Trop Med Int Health. 2005 Nov;10(11):1090-8.

8.

Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.

Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, Memish Z, Khan K, Gardam M, Hoeppner V, Benedetti A, Schwartzman K.

Ann Intern Med. 2008 Nov 18;149(10):689-97.

PMID:
19017587
9.

A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.

Bock NN, Sterling TR, Hamilton CD, Pachucki C, Wang YC, Conwell DS, Mosher A, Samuels M, Vernon A; Tuberculosis Trials Consortium, Centers for Disease Control and Prevention, Atlanta, Georgia.

Am J Respir Crit Care Med. 2002 Jun 1;165(11):1526-30.

PMID:
12045127
11.

Treatment of latent tuberculosis infection.

Parekh MJ, Schluger NW.

Ther Adv Respir Dis. 2013 Dec;7(6):351-6. doi: 10.1177/1753465813503028. Epub 2013 Sep 20. Review.

PMID:
24056289
12.

Treatment of latent tuberculosis infection: An update.

Lobue P, Menzies D.

Respirology. 2010 May;15(4):603-22. doi: 10.1111/j.1440-1843.2010.01751.x. Epub 2010 Apr 7. Review.

PMID:
20409026
13.

Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2011 Dec 9;60(48):1650-3. Erratum in: MMWR Morb Mortal Wkly Rep. 2012 Feb 3;61:80.

14.

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.

Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team.

N Engl J Med. 2014 Oct 23;371(17):1599-608. doi: 10.1056/NEJMoa1314210.

15.

Treatment of latent tuberculosis infection in HIV: shorter or longer?

Person AK, Sterling TR.

Curr HIV/AIDS Rep. 2012 Sep;9(3):259-66. doi: 10.1007/s11904-012-0120-1. Review.

16.

[Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis].

Martínez Alfaro E, Solera J, Serna E, Cuenca D, Castillejos ML, Espinosa A, Sáez L.

Med Clin (Barc). 1998 Oct 10;111(11):401-4. Spanish.

PMID:
9834911
17.

Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.

Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, Baruch N, Adelakun A, Dorman SE.

Arch Intern Med. 2006 Sep 25;166(17):1863-70.

PMID:
17000943
18.
19.

Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.

Cook PP, Maldonado RA, Yarnell CT, Holbert D.

Clin Infect Dis. 2006 Aug 1;43(3):271-5. Epub 2006 Jun 22.

20.

Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates.

de Castilla DL, Rakita RM, Spitters CE, Narita M, Jain R, Limaye AP.

Transplantation. 2014 Jan 27;97(2):206-11. doi: 10.1097/TP.0b013e3182a94a2f.

PMID:
24142036
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk